Journal Highlight : Cancer Biomarkers and Molecular Diagnostics
The journal welcomes scholarly contributions related to the discovery, validation, and clinical application of biomarkers and diagnostic technologies in cancer research and oncology practice. This section focuses on research that improves early cancer detection, disease classification, prognostic evaluation, therapeutic decision-making, and treatment monitoring through molecular and clinical diagnostic advancements.
The journal encourages submissions in areas including Cancer Biomarkers, Molecular Diagnostics, Genomic and Proteomic Biomarkers, Liquid Biopsy Technologies, Companion Diagnostics, Tumor Profiling, Circulating Tumor Cells, Circulating Tumor DNA, Immunodiagnostics, and Predictive and Prognostic Biomarkers. Research related to Next-Generation Sequencing, Molecular Pathology, Cancer Imaging Diagnostics, Epigenetic Biomarkers, Transcriptomics and Proteomics, and AI-Assisted Diagnostic Technologies is also welcomed.
Submissions focusing on Early Cancer Detection, Precision Diagnostics, Biomarker Validation Studies, Disease Monitoring and Treatment Response Assessment, Personalized Oncology Approaches, Diagnostic Accuracy and Clinical Utility, Screening Strategies, and Bioinformatics Applications in Cancer Diagnostics are encouraged. The journal also welcomes studies investigating biomarker-guided therapeutic strategies, resistance prediction, recurrence monitoring, and translational applications of diagnostic technologies in oncology.
Accepted manuscript types include Original Research Articles, Systematic Reviews, Meta-Analyses, Clinical and Translational Studies, Diagnostic Evaluation Studies, Case Reports, Technology and Methodology Articles, and Clinical Trial Reports that contribute to advancements in oncology biomarkers and cancer diagnostics.
Through this focus area, the journal aims to support research that advances molecular and clinical diagnostics, improves biomarker-driven cancer care, enhances early detection and therapeutic precision, and contributes to innovative and evidence-based oncology practices worldwide.
